NAD+ Where to Buy: The Questions a Sourcing Pharmacist Asks

Most compounds we write about here have a blunt availability answer: no pharmacy stocks them, no clinician can lawfully write for them, and the only route is a vial of research material. NAD+ is not that shape of problem. Infusion bars, med spas and longevity practices advertise NAD+ drips openly, and a compounding pharmacy can prepare a preparation for a prescriber without hiding. The question stops being who is willing to sell to you and becomes what grade of powder you are paying for.

That reframing is not rhetorical. FDA sets an explicit sourcing rule for pharmacies compounding with bulk drug substances: the substance must be accompanied by a valid certificate of analysis, and it must have been manufactured by an establishment registered with FDA under section 510 of the Federal Food, Drug and Cosmetic Act. The rule is stated plainly on FDA's bulk drug substances page. Nothing obliges a research-chemical supplier to meet that bar. Everything about whether your purchase is defensible depends on how close it gets.

This page ends with a supplier we earn a commission from, which our affiliate disclosure sets out in full. It also names the lines on this checklist our own pick has not published, because a checklist only its author's favourite passes is not a checklist.

Start with the one document that should change how you read every NAD+ listing on the internet. FDA published a compounding risk notice, content current as of 30 October 2024, saying the agency "is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products." The notice continues: "Ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins."

Then the part that turns a technical point into a purchase criterion. FDA states it "has received adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue with some requiring medical treatment," and that "these reactions are consistent with excessive levels of endotoxins." The full text is on FDA's notice to compounders, and it is the single most useful thing anyone can hand a person about to buy this compound.

Read what that describes. Not a back-bedroom operation: licensed compounders, buying from repackagers, putting material never intended for injection into intravenous products. If that can happen inside the regulated channel, a research listing that says nothing at all about grade is not reassuring by omission.

So the first question you ask any NAD+ seller, in writing, before money moves, is whether the material is pharmaceutical grade or food grade, and where the source material came from. A vendor that answers cleanly has told you something. A vendor that answers with a purity percentage has changed the subject, and a vendor that does not answer at all has answered.

Almost every NAD+ listing worth considering publishes a certificate, and almost all publish the same two tests. High performance liquid chromatography tells you how much of the sample is the compound you ordered. Mass spectrometry confirms it is that compound. Both cost money to run, and neither answers the question that put people in a clinic chair with severe chills.

The test that answers it is bacterial endotoxins testing, usually the LAL assay, and it is reported in endotoxin units rather than as a percentage. FDA maintains a guidance on pyrogen and endotoxins testing if you want the underlying framework. In plain terms: a sample can be 99 percent pure by HPLC and still carry a load of bacterial cell-wall fragments that a purity assay is not looking for and will never report.

The other half of the certificate question is whether it belongs to your material at all. A batch-specific certificate names a lot number you can match against the vial in your hand. A generic certificate describes a batch that existed once, possibly years ago, at a facility the seller may no longer use. If the lot on the paperwork does not match the lot on the label, you have a well formatted PDF and nothing else.

The remaining criteria are about what happens when something goes wrong. Domestic stock matters more for NAD+ than for a small peptide vial, because a gram in transit for three weeks through a customs queue has spent three weeks somewhere nobody was monitoring the temperature. A published same-day dispatch cutoff is indirect evidence the material already sits in a warehouse in the country rather than being drop-shipped after you pay.

A written refund and replacement policy is the other one, not because you expect to use it but because a business willing to write one has accepted that it is the seller of record. Sellers taking bank transfers or peer-to-peer payments with no published policy have arranged things so the transaction ends when your money leaves.

The last practical criterion is the one people find counterintuitive: a good supplier publishes no human dosing guidance. Research material is sold on the basis that it is not for human consumption, and a storefront that pairs a research-use label with an infusion protocol has contradicted its own legal position on the same page. Our scam checker runs a version of this logic against a specific offer if you want to test one you are looking at.

NAD+ sits in an unusual position, and getting it right separates a useful page from the several that get it backwards. Nicotinamide adenine dinucleotide appears in FDA's category 1 list of bulk drug substances under evaluation, in the category list updated 14 May 2026. Category 1 means FDA does not intend to take action against a compounder using the substance provided the conditions in its guidance are met. That is a non-enforcement position while evaluation is pending. It is not approval, it is not permanent, and anyone who reports it as a clean bill of health has misread it.

Practically, it means the clinic channel for NAD+ is not automatically illegitimate the way it would be for an investigational drug with no approved reference product. A compounding pharmacy really can prepare one for a prescriber. That is a different transaction from the one on this page, with a different accountability chain and a different price, and our companion piece on buying NAD+ without a prescription works through it properly.

Ascension Peptides is the supplier we link, and the honest scoring is mixed rather than glowing. On stock and dispatch it does well: a published 2pm CST cutoff for same-day shipping, Monday through Saturday, which is only possible with material already in a US facility. On price transparency it does well: one listing, NAD+ 1,000 mg, $104.00 at list and $52.00 with the code PEPTIDEDECK, which is $5.20 per 100 mg. Quantity tiers of three, five and ten units take 3, 5 and 10 percent off the list price, and nothing published says the code stacks with them, so read them as alternatives rather than as a combination. Free shipping starts at $250.

On testing it states that two independent laboratories test every batch, which is more than most of this market publishes and less than this compound specifically requires. Before ordering, open the certificate on the NAD+ listing and check two things: that the lot number matches the vial you receive, and that the reported tests include bacterial endotoxins and not only identity and purity. We have not run these analyses ourselves.

What it does not have is anything this category can have. No prescriber, no pharmacist checking the preparation, no label, no follow-up, no recall that reaches you. The product page carries no dosing guidance either, which is correct for a research sale and is also why the box contains nothing but the vial. If those gaps matter to you, the checklist has not failed; your requirements have pointed at a different channel, which our channel comparison lays out side by side.

Here is the whole page compressed. Read the third column first, because it is the one that turns an abstract standard into a decision you can make from a browser tab in about ten minutes.

One caveat. No supplier in this market passes every line, including ours, and a page claiming otherwise is selling. The point is to know which gaps you are choosing to accept rather than to find them afterwards.

NAD+ where to buy has three real answers, and they are not competing for the same reader. A clinic sells the infusion, the chair and the person watching you. A compounding pharmacy, with a prescriber, sells a preparation made under a sourcing rule FDA enforces. A research supplier sells a gram of powder for $52.00 and nothing else.

If you take the third route, take it with the checklist intact and the FDA notice in mind, because the failure mode it describes is not theoretical and it did not happen in the disreputable part of the market. Ask about grade. Ask for a lot-matched certificate. Ask whether endotoxins were tested. A supplier that answers all three has earned the order, and one that dodges any of them has told you what the discount is paying for.

If what you want is a clinician and an accountable chain, that exists for this compound in a way it does not for most of what we cover, and it is not on this page. Our methodology explains how we assess the regulated side.